Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19
The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect sus...
Gespeichert in:
| Veröffentlicht in: | American journal of hypertension Jg. 34; H. 3; S. 278 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
02.04.2021
|
| Schlagworte: | |
| ISSN: | 1941-7225, 1941-7225 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19.
In this prospective single-center study, we determined the serum levels of ACE2, angiotensin II, and aldosterone in patients with COVID-19 compared with control patients presenting with similar symptoms in the emergency unit.
We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms, and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups.
In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19.
Trial Number DRKS00021206. |
|---|---|
| AbstractList | The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19.
In this prospective single-center study, we determined the serum levels of ACE2, angiotensin II, and aldosterone in patients with COVID-19 compared with control patients presenting with similar symptoms in the emergency unit.
We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms, and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups.
In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19.
Trial Number DRKS00021206. The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19.BACKGROUNDThe role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19.In this prospective single-center study, we determined the serum levels of ACE2, angiotensin II, and aldosterone in patients with COVID-19 compared with control patients presenting with similar symptoms in the emergency unit.METHODSIn this prospective single-center study, we determined the serum levels of ACE2, angiotensin II, and aldosterone in patients with COVID-19 compared with control patients presenting with similar symptoms in the emergency unit.We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms, and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups.RESULTSWe analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms, and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups.In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19.CONCLUSIONSIn summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19.Trial Number DRKS00021206.CLINICAL TRIALS REGISTRATIONTrial Number DRKS00021206. |
| Author | Duerschmied, Daniel Hofmann, Maike Rieder, Marina Busch, Hans-Joerg Lother, Achim Schmid, Bonaventura Baldus, Niklas Jeserich, Maren Wirth, Luisa Bode, Christoph Goller, Isabella Pollmeier, Luisa Kern, Winfried |
| Author_xml | – sequence: 1 givenname: Marina surname: Rieder fullname: Rieder, Marina organization: Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 2 givenname: Luisa surname: Wirth fullname: Wirth, Luisa organization: Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 3 givenname: Luisa surname: Pollmeier fullname: Pollmeier, Luisa organization: Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 4 givenname: Maren surname: Jeserich fullname: Jeserich, Maren organization: Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 5 givenname: Isabella surname: Goller fullname: Goller, Isabella organization: Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 6 givenname: Niklas surname: Baldus fullname: Baldus, Niklas organization: Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 7 givenname: Bonaventura surname: Schmid fullname: Schmid, Bonaventura organization: Department of Emergency Medicine, University Hospital of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 8 givenname: Hans-Joerg surname: Busch fullname: Busch, Hans-Joerg organization: Department of Emergency Medicine, University Hospital of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 9 givenname: Maike surname: Hofmann fullname: Hofmann, Maike organization: Medical Center-University of Freiburg, Department of Medicine II, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 10 givenname: Winfried surname: Kern fullname: Kern, Winfried organization: Medical Center-University of Freiburg, Division of Infectious Diseases, Department of Medicine II, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 11 givenname: Christoph surname: Bode fullname: Bode, Christoph organization: Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 12 givenname: Daniel surname: Duerschmied fullname: Duerschmied, Daniel organization: Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 13 givenname: Achim surname: Lother fullname: Lother, Achim organization: Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33043967$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1Lw0AYhBep2A89eZc9emjsfqd7DLFqoFBBq-AlbLJvm5RkU7OJ4L83YAVPM4eHmWGmaOQaBwhdU3JHieYLcygWxdEYqvQZmlAtaBAyJkf__BhNvT8QQoRS9AKNOSeCaxVO0McLtH2No3jF5jhy-7LpwPnS4SSZY-Msjirb-A7aoROv4Qsqj6MW8NblhXF7sHhgn01Xgus8fi-7Asebt-Q-oPoSne9M5eHqpDO0fVi9xk_BevOYxNE6yLkMu8AOuzkDneVaCyEIA5MRTmGpmVKSASchUdIqlTO95LtMGEGt1HYJcmcU1WyGbn9zj23z2YPv0rr0OVSVcdD0PmVCaK0lJXRAb05on9Vg02Nb1qb9Tv_-YD_SemBg |
| CitedBy_id | crossref_primary_10_3389_fcvm_2022_847809 crossref_primary_10_3389_fmed_2022_1058120 crossref_primary_10_1042_BST20241052 crossref_primary_10_3390_cells10030650 crossref_primary_10_1016_j_ijid_2021_11_028 crossref_primary_10_1093_ajh_hpaa178 crossref_primary_10_2174_1874467214666210902115650 crossref_primary_10_1016_j_ijcard_2022_10_172 crossref_primary_10_1093_ajh_hpaa175 crossref_primary_10_1186_s12879_024_09310_3 crossref_primary_10_3390_pharmaceutics14091906 crossref_primary_10_3390_microorganisms12010229 crossref_primary_10_1007_s10096_020_04138_6 crossref_primary_10_1016_j_bcp_2022_115370 crossref_primary_10_1080_00365513_2021_1926536 crossref_primary_10_1186_s12950_023_00333_2 crossref_primary_10_1007_s15027_021_3471_y crossref_primary_10_1016_j_advms_2025_02_002 crossref_primary_10_1016_j_microc_2024_111592 crossref_primary_10_3390_ijms232214193 crossref_primary_10_1002_prot_26140 crossref_primary_10_1016_j_metabol_2024_155980 crossref_primary_10_3390_jcm11226799 crossref_primary_10_1186_s12931_023_02469_4 crossref_primary_10_1111_jdv_17723 crossref_primary_10_3389_fmicb_2022_1042200 crossref_primary_10_1161_CIRCRESAHA_122_320873 crossref_primary_10_1530_EC_22_0190 crossref_primary_10_1128_msphere_00220_22 crossref_primary_10_3389_fimmu_2022_836516 crossref_primary_10_3389_fimmu_2021_612807 crossref_primary_10_3390_cells10102755 crossref_primary_10_1097_CCM_0000000000005589 crossref_primary_10_1038_s41577_021_00634_8 crossref_primary_10_3390_jpm12040622 crossref_primary_10_1007_s12020_021_02968_8 crossref_primary_10_1177_17534666221122544 crossref_primary_10_3389_fncel_2023_1111263 crossref_primary_10_5812_ijpr_137832 crossref_primary_10_1055_s_0043_1777840 crossref_primary_10_1631_jzus_B2300512 crossref_primary_10_1210_jendso_bvad015 crossref_primary_10_3389_fimmu_2022_1001951 crossref_primary_10_1016_j_peptides_2022_170848 crossref_primary_10_1038_s41598_022_24628_1 crossref_primary_10_3389_fcvm_2024_1488226 crossref_primary_10_1161_HYPERTENSIONAHA_121_17674 crossref_primary_10_1089_ars_2021_0017 crossref_primary_10_1016_j_phrs_2021_105929 crossref_primary_10_1007_s11357_022_00528_0 crossref_primary_10_1016_j_biochi_2022_06_005 crossref_primary_10_12998_wjcc_v10_i34_12470 crossref_primary_10_1016_j_ejim_2021_09_007 crossref_primary_10_3390_diagnostics14111194 crossref_primary_10_1186_s13613_025_01433_3 crossref_primary_10_1093_ajh_hpaa188 crossref_primary_10_1097_HJH_0000000000003054 crossref_primary_10_34067_KID_0001562021 crossref_primary_10_1016_j_ajpath_2021_12_011 crossref_primary_10_3389_fphar_2022_798349 crossref_primary_10_1093_ajh_hpab033 crossref_primary_10_3389_fphys_2020_622179 crossref_primary_10_1007_s11154_021_09663_z crossref_primary_10_1096_fj_202100051R crossref_primary_10_1016_j_biopha_2022_113201 crossref_primary_10_1016_j_bcp_2022_115183 crossref_primary_10_3389_fmed_2023_1287066 crossref_primary_10_1161_CIRCRESAHA_123_321883 crossref_primary_10_1186_s10194_021_01306_7 crossref_primary_10_1007_s11033_023_08515_0 |
| ContentType | Journal Article |
| Copyright | American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/ajh/hpaa169 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1941-7225 |
| ExternalDocumentID | 33043967 |
| Genre | Comparative Study Clinical Study Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GroupedDBID | --- .2P .I3 .ZR 0R~ 23M 39C 4.4 48X 53G 5GY 5RE 5WD 70F AABZA AACZT AAFWJ AAJKP AAMVS AAOGV AAPQZ AAPXW AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFS ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGORE AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AJBYB AJEEA AJNCP AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT ATGXG AVWKF AXUDD BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF DAKXR DILTD D~K EBS ECM EE~ EIF EMOBN ENERS F5P F9B FDB FECEO FLUFQ FOEOM FOTVD FQBLK G-Q GAUVT GJXCC H13 H5~ HAR HW0 HZ~ J21 JXSIZ KBUDW KOP KSI KSN MHKGH ML0 NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OPAEJ OVD OWPYF O~Y P2P PAFKI PEELM Q1. Q5Y ROX RPZ RUSNO RW1 RXO TEORI TJX WH7 YAYTL YKOAZ YXANX 7X8 |
| ID | FETCH-LOGICAL-c357t-d16932e9bc9944402eab031e8926652e307065d66c2983fb4a41d59d8e5fa6192 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 84 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000642297400009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1941-7225 |
| IngestDate | Sun Sep 28 12:07:23 EDT 2025 Mon Jul 21 05:36:49 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | COVID-19 ACE2 blood pressure SARS-CoV-2 aldosterone angiotensin II hypertension |
| Language | English |
| License | American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c357t-d16932e9bc9944402eab031e8926652e307065d66c2983fb4a41d59d8e5fa6192 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/ajh/article-pdf/34/3/278/46285122/hpaa169.pdf |
| PMID | 33043967 |
| PQID | 2449995101 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2449995101 pubmed_primary_33043967 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-02 |
| PublicationDateYYYYMMDD | 2021-04-02 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | American journal of hypertension |
| PublicationTitleAlternate | Am J Hypertens |
| PublicationYear | 2021 |
| References | 33156903 - Am J Hypertens. 2021 Apr 2;34(3):296-297 |
| References_xml | – reference: 33156903 - Am J Hypertens. 2021 Apr 2;34(3):296-297 |
| SSID | ssj0004661 |
| Score | 2.5843441 |
| Snippet | The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 278 |
| SubjectTerms | Aldosterone - blood Angiotensin II - blood Angiotensin-Converting Enzyme 2 - blood Angiotensin-Converting Enzyme Inhibitors - therapeutic use Blood Pressure Determination - statistics & numerical data COVID-19 - blood COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - physiopathology Female Germany - epidemiology Humans Hypertension - blood Hypertension - drug therapy Hypertension - epidemiology Hypertension - physiopathology Male Middle Aged Outcome Assessment, Health Care Potassium - blood Prospective Studies Renin-Angiotensin System - physiology SARS-CoV-2 - isolation & purification |
| Title | Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33043967 https://www.proquest.com/docview/2449995101 |
| Volume | 34 |
| WOSCitedRecordID | wos000642297400009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UinhxX-rGCB4baraZzElCrVhoaw-2Fi8lybzYiia1af39vpek6EkELzkl4fH43r4xdhWaVL0B0wDHAgxQAEUKQteIMXqOY9MGmbf8D9qy2_WGQ9UrE25Z2Va51Im5otZpRDnyOpoh9GUIQTfTD4OuRlF1tTyhscoqNlXcEM9y-GNbuCj2pSrHNCQCt5zPQzLqweu4Pp4GgSl-8S1zG3O3_V_qdthW6V1yv4DDLluBZI9tdMr6-T57RtWweOd-o2nVuJ-8TNK8gT3hrVaNB4nm_pumqY9ZmgBvUz9Rhj8D3k-KAWHN8d1esYo140-T-Zg3HgatW8NUB6x_13xs3BvldQUjsl05NzStYbFAhZFSjoNhJAQhSjh4Cm22awEpA-FqISJLeXYcOoFjaldpD9w4oLDrkK0lSM0x4xr9QilCFzza1XMde7FnSTOiG_Z25Ai7yi6XXBsheqkkESSQLrLRN9-q7Khg_WharNkYUabFVkKe_OHrU7ZpUbMJtdRYZ6wSo-zCOVuPPueTbHaRwwKf3V7nC_LgvmU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+ACE2%2C+Angiotensin+II%2C+and+Aldosterone+Levels+Are+Unchanged+in+Patients+With+COVID-19&rft.jtitle=American+journal+of+hypertension&rft.au=Rieder%2C+Marina&rft.au=Wirth%2C+Luisa&rft.au=Pollmeier%2C+Luisa&rft.au=Jeserich%2C+Maren&rft.date=2021-04-02&rft.issn=1941-7225&rft.eissn=1941-7225&rft.volume=34&rft.issue=3&rft.spage=278&rft_id=info:doi/10.1093%2Fajh%2Fhpaa169&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-7225&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-7225&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-7225&client=summon |